The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial
出版年份 2019 全文链接
标题
The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial
作者
关键词
Everolimus, Cyclophosphamide, mRCC, Tregs, mTOR, Immune monitoring
出版物
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2019-01-17
DOI
10.1007/s00262-018-2288-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
- (2018) Charlotte M. Huijts et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions
- (2018) Aly-Khan A. Lalani et al. EUROPEAN UROLOGY
- Immunological effects of everolimus in patients with metastatic renal cell cancer
- (2017) Charlotte M Huijts et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy
- (2016) Thomas Powles et al. EUROPEAN UROLOGY
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours
- (2016) Holger Moch et al. EUROPEAN UROLOGY
- FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
- (2016) MASARU KATOH INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma
- (2016) Robert J Motzer et al. LANCET ONCOLOGY
- Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
- (2016) Alena Gros et al. NATURE MEDICINE
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
- (2015) Bin Shang et al. Scientific Reports
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer
- (2013) Claudia C. Preston et al. PLoS One
- Substantially Modified Ratios of Effector to Regulatory T Cells During Chemotherapy in Ovarian Cancer Patients Return to Pre-Treatment Levels at Completion: Implications for Immunotherapy
- (2012) Anthony Park et al. Cancers
- Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
- (2011) Charlotte M Huijts et al. BMC CANCER
- CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes
- (2011) Fangfang Liu et al. BREAST CANCER RESEARCH AND TREATMENT
- Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome
- (2011) Yingzi Ge et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma
- (2008) Jin F. Li et al. BJU INTERNATIONAL
- Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival
- (2008) H. van Cruijsen et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started